Global data is sending mixed signals on growth, inflation and interest rates, yet one trend cuts through the noise: healthcare is increasingly turning to artificial intelligence to do more with limited resources. While manufacturing and services readings flicker between strength and softness across major regions, AI healthcare tools are being built to improve accuracy, reduce waste and speed up research regardless of the macro backdrop. The Transformative AI Healthcare Stocks screener focuses on companies tied to this shift. In this article, you will see three stocks from the screener that exemplify this theme.

Butterfly Network (BFLY)

Overview: Butterfly Network is a medical technology company that makes handheld ultrasound devices that connect to smartphones, tablets, and hospital systems, aiming to bring whole body imaging to the bedside and beyond. It also offers AI software and education tools to help clinicians and veterinarians capture and interpret scans more easily in everyday practice.

Operations: Butterfly Network generates about US$102.9 million in revenue mainly from its AI enhanced personal ultrasound solution, with roughly US$81.8 million from the United States and US$21.2 million from international markets.

Market Cap: US$1.90b

Investors looking at Butterfly Network are really weighing the promise of its ultrasound on chip technology and AI tools like Compass AI against meaningful financial risks. The company is currently loss making, with a high P/S multiple and funding largely reliant on external borrowing, which raises questions about valuation and balance sheet resilience. At the same time, management has set earnings and revenue growth targets that, if achieved, could move the business toward profitability over the next few years. The Midjourney collaboration, potential licensing income and FDA cleared AI tools such as the gestational age product all point to a broader role in AI powered imaging. However, recent insider selling and share price volatility indicate that this is not a low risk story.

Butterfly Network’s AI ultrasound story is accelerating, but the real tension lies between its growth ambitions and balance sheet pressure. Get the full picture in the 1 key reward and 2 important warning signs (1 is major!)

Pfizer (PFE)

Overview: Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines across areas such as cardiovascular disease, migraine, inflammation, rare diseases, infectious disease, and cancer, including brands like Eliquis, Prevnar, Paxlovid, Ibrance, and Xtandi.

Operations: Pfizer generates about US$63.2b in revenue, with around US$61.9b from its Global Biopharmaceuticals Business and the remainder from segment adjustments, while sales are spread across the United States, developed markets, and emerging markets.

Market Cap: US$142.9b

Pfizer offers a mix many income focused investors look for: a high dividend yield around 6% and a broad portfolio in areas like oncology, rare disease, and obesity, where new AI supported R&D tools are intended to speed up drug discovery and improve efficiency. At the same time, revenue and earnings are forecast to decline in the near term, dividend coverage is tight, and a recent US$10.7b one off loss plus a CFO transition underline that execution risk is real. For investors, the interest lies in whether a deep late stage pipeline, cost savings plans, and AI partnerships can offset patent expiries and funding pressures before the balance sheet or payout policy need a rethink.

Pfizer’s high yield and AI supported pipeline could be masking a much bigger story about how sustainable its payout and balance sheet really are, and the answer sits inside the 1 key reward and 4 important warning signs (3 are major!)

Stryker (SYK)

Overview: Stryker is a medical technology company that supplies hospitals and surgeons with equipment for joint replacement, trauma care, brain and spine procedures, and AI assisted virtual care platforms used in operating rooms and intensive care settings across about 61 countries.

Operations: Stryker generates roughly US$9.5b from its Orthopaedics segment and about US$15.8b from MedSurg and Neurotechnology products.

Market Cap: US$116.8b

Stryker interests many investors because it sits at the crossroads of an aging population, rising surgical volumes and hospital digitization. It ties those trends to concrete products such as robotic assisted Mako procedures, AI supported virtual care and new tools including the Pangea Plating System and TPX HD small bone power platform. Earnings have been growing, margins are improving, and analysts currently expect further upside in revenue and profit. At the same time, the stock carries a rich valuation and high debt, and there are signs of caution such as insider selling and tariff or regulatory risk around new product launches. For anyone tracking how AI and robotics are reshaping operating rooms, Stryker’s mix of growth potential and balance sheet pressure may warrant closer attention.

Stryker’s accelerating mix of AI assisted surgery and richer margins raises a key question about whether the valuation and debt load truly fit the story, and the answer lies within the 4 key rewards and 2 important warning signs

The three stocks in this article are only a starting point, and the full screener has surfaced 35 more companies with equally compelling AI in healthcare stories inside the Transformative Artificial intelligence (AI) Healthcare Stocks screener. Identify and analyze the specific catalysts and narratives that matter to you, from AI powered diagnostics to drug discovery and virtual care, so you can focus on the highest conviction opportunities.

Take Control of Your Investment Journey

If Stryker or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Healthcare AI?

Markets move fast, and the best ideas rarely stay under the radar for long. Before the crowd catches on and momentum takes off or drops away, act now.

• Spot underappreciated cash generators by scanning a curated 44 high quality undervalued stocks that are built on strong balance sheets and cash flows before attention and prices start flying.
• Zero in on durable income opportunities with a hand picked 7 dividend fortresses so you can pursue yield potential while payouts and entry points still look fresh.
• Ride the build out of tomorrow’s infrastructure by reviewing a focused 49 AI infrastructure stocks that could benefit from AI momentum while it is still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.